Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy

Condition:   Thyroid Cancer Intervention:   Drug: dabrafenib and trametinib Sponsors:   National University Hospital, Singapore;   Singapore General Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials